Retraction Note: Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer

Donge Tang^#^{1

2}, Jiaxi He^#³, Yong Dai^#², Xinyan Geng⁴, Qixin Leng³, Haowu Jiang⁵, Rui Sun⁶, Songhui Xu^{7

8}

Affiliations

¹ Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
² Department of Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
³ Department of Pathology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
⁴ Department of Biochemistry, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
⁵ Department of Anesthesiology and Center for the Study of Itch, Washington University School of Medicine, St. Louis, MO, USA.
⁶ Department of Internal Medicine, Yale University, New Haven, CT, USA.
⁷ Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. songhuixu007@gmail.com.
⁸ Department of Pathology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. songhuixu007@gmail.com.

^# Contributed equally.

Donge Tang et al. Cancer Gene Ther. 2023 Oct.

. 2023 Oct;30(10):1442.

doi: 10.1038/s41417-023-00669-0.

Donge Tang^#^{1

2}, Jiaxi He^#³, Yong Dai^#², Xinyan Geng⁴, Qixin Leng³, Haowu Jiang⁵, Rui Sun⁶, Songhui Xu^{7

8}

¹ Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
² Department of Clinical Medical Research Center, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, Guangdong, China.
³ Department of Pathology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
⁴ Department of Biochemistry, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
⁵ Department of Anesthesiology and Center for the Study of Itch, Washington University School of Medicine, St. Louis, MO, USA.
⁶ Department of Internal Medicine, Yale University, New Haven, CT, USA.
⁷ Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China. songhuixu007@gmail.com.
⁸ Department of Pathology, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA. songhuixu007@gmail.com.

^# Contributed equally.

No abstract available

Retraction of

Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer.
Tang D, He J, Dai Y, Geng X, Leng Q, Jiang H, Sun R, Xu S. Tang D, et al. Cancer Gene Ther. 2022 May;29(5):543-557. doi: 10.1038/s41417-021-00332-6. Epub 2021 Apr 14. Cancer Gene Ther. 2022. Retraction in: Cancer Gene Ther. 2023 Oct;30(10):1442. doi: 10.1038/s41417-023-00669-0. PMID: 33854217 Retracted.

1. Tang D-E, Dai Y, He J-X, Lin L-W, Leng Q-X, Geng X-Y, et al. Targeting the KDM4B–AR–c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer. J Pathol. 2020;252:101–13.e5495. https://doi.org/10.1002/path.5495 . - DOI - PubMed